---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002893"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:02:10.151463+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences nominates first herpesvirus candidate ABI-5366, a long-acting HSV-2 helicase inhibitor

## Summary
- ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.
- Preclinical data show nanomolar potency in vitro and exceptionally low clearance, supporting at least monthly dosing.
- Company plans to file IND/CTA in first half of 2024; more data expected at scientific conferences in 2023.
- First development candidate from Assembly Bio's expanded focus beyond hepatitis B.
- Current therapies for high-recurrence genital herpes are only partially effective; helicase inhibitors previously showed greater reductions in shedding and lesions.

## SEC filing metadata
- accession: 0000950170-23-002893
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/0000950170-23-002893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/asmb-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002893
- JSON: https://secwatch.observer/filing/0000950170-23-002893.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.